Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| First of all, we feel very good about the momentum in our business |
| Performance in the quarter benefited from double-digit growth in all key product categories within the division, including our care communications, surgical solutions and Patient Support Systems product offerings |
| Yesterday, we just got awarded best-in-class KLA for our Sigma Spectrum pump, which is a great honour |
| And also, there are some very important accounts that we – is still closing on for the rest of the year that we will also boost our ability to do well in 2024 |
| Relative to expectations, both of our chronic therapies and drug compounding divisions reported better-than-expected sales |
| Our fourth quarter results further reinforce our building momentum |
| Similarly, I think we will see sequential improvement for capital orders within our CCS business every quarter this year, leading to orders being up on a year-over-year basis |
| As a testament to this focus, over the course of 2023, we were able to deliver sequential improvement every quarter, and we believe this performance provides us with a solid foundation to build off in 2024 |
| So think about our objective in 2024 into 2025 is to continue to add value and significant accretion potentially to the bottom line by getting those contracts signed, but we are in good position |
| So earnings growth in the first half of the year will be very strong |
| If you remember in the last quarter, our HST business, we’re very pleased with the momentum we had from a sales perspective in Q4, and we do anticipate that heading into the year as well |
| Performance in these segments was filled by strong execution across our commercial and manufacturing teams |
| I think in all those areas, we feel good about the opportunities again to build on momentum we’ve had |
| So this is a really good momentum for Baxter |
| The underlying state of the Kidney Care business continues to improve and the momentum we are building is evident |
| I said we feel really good about that |
| Our strategic rationale and hypothesis for an independent Kidney Care business remains as strong as ever |
| If you think about the full year guidance itself, a couple some of that strong sales performance with the fact that we’re actually expanding our margins by over 50 basis points – and we’re actually leading to double-digit EPS growth |
| Given overall business performance and environmental dynamics, I’m optimistic as we look ahead to the prospects for both Baxter and Vantive as separate entities |
| Our solid financial performance was achieved in parallel with meaningful progress against the strategic priorities we announced to open 2023 |
| We are well poised to take that action |
| A business that is very predictable is our MPT business, which has been successfully growing, as you can see in 2023 |
| And the other thing I would say that we’ve done a good job of – are going to continue to do an even better job of is to give ourselves the opportunities to actually have indexes within our pricing that allow us more flexibility to pass along cost that are coming into our world that we have historically struggled to pass along to our customers |
| We are already seeing the benefits of improved line of sight to our customers and greater agility to recognize and capture growth opportunities |
| We are pleased with some of the results that we have heading into this year |
| I think we had a – we saw a solid fourth quarter |
| On a constant currency basis, sales increased 3%, also ahead of our guidance, which projected growth of approximately 1% |
| Sales from continuing operations rose 4% on a reported basis ahead of our outlook of 1% to 2% growth |
| As I said before, we just got an award a best-in-class for that pump, and we’re very happy, and we continue to be very busy quoting new accounts and competitive accounts, which we are actually winning with that pump |
| And it is important to note that our teams were able to achieve this performance, while also making meaningful progress against our strategic initiatives designed to enhance our future performance and drive incremental value for all stakeholders |
| Statement |
|---|
| Other sales, which represent sales not allocated to a segment and primarily include sales of products and services provided directly through certain of our manufacturing facilities were $18 million and declined 58% during the quarter in line with our expectations |
| Finally, performance in chronic therapies continues to be impacted by lower sales in China due to certain government-based procurement initiatives and a lower patient census due to the pandemic |
| I talked about it being kind of negative on the operating margin |
| This lower level of sales reflects reduced demand for certain contract manufacturing volumes and the termination of a royalty arrangement |
| We estimate that collectively, these country-specific factors negatively impacted sales by approximately $35 million in the quarter |
| For the full year, Baxter’s adjusted earnings from continuing operations decreased 14% to $2.60 per diluted share, reflecting the impact of higher cost of goods sold, driven primarily by the macro environmental factors we previously discussed, greater annual employee bonus accruals, as well as increased non-operating expenses |
| Factors impacting year-over-year growth are primarily driven by select market and product exits in connection with our margin expansion initiatives for this segment which we estimate will negatively impact sales by approximately $150 million |
| And so as a result, we entered into some MSAs, which will have a negative impact on the pharmaceutical margins and obviously on total Baxter margins for the year as we’ve now entered into the MSA |
| So all in, our non-op is probably a couple of cents negative impact for us on the year |
| Moving on to Kidney Care, sales in the quarter were $1.2 billion and declined 1% |
| As expected, Kidney Care sales declined slightly in the quarter due to the factors Joe mentioned earlier |
| Your question on FX, Travis was FX is negative on margins for the year, about 40 basis points of an impact on our operating margins on a year-over-year basis |
| There’s a bit of an early headwind on that business during the first part of the year as well |
| hospital customers, we continue to believe there may still be select pockets of cautiousness in the marketplace |
| Strong growth in acute therapies was offset by flat growth in chronic therapies, reflecting a difficult year-over-year comparison due to certain discrete items that benefited sales in the prior year as well as lower sales in China due to the impact of government-based procurement initiatives and the lower patient census due to the pandemic |
| Is that the right way to look at – is that the right way to look at it longer term? And similarly, in the renal business itself, you’re expecting 1% to 2% decline this year |
| We see hospitals a little bit more cautious in the first quarter |
| Our Kidney Care segment, which will be called Vantive post separation, declined 1% in the quarter and grew 1% for the year at constant rates |
| You talked about the capital equipment environment continuing to improve some pockets of weakness |
| Sales growth in the quarter was impacted by a difficult comparison to the prior year period, which included certain discrete items in the U.S |
Please consider a small donation if you think this website provides you with relevant information